Metopimazine is a phenothiazine-derived antiemetic drug developed in the mid-20th century and used primarily for the treatment of nausea and vomiting, including those associated with gastrointestinal disorders, motion sickness, and postoperative conditions. Its history is characterized by its peripheral dopamine D2 receptor antagonism, which reduces stimulation of the chemoreceptor trigger zone in the brainstem, thereby controlling emesis. Unlike some other phenothiazines, metopimazine has limited central nervous system penetration, which reduces sedative and extrapyramidal side effects. Over time, it has been used in select countries as a safer alternative antiemetic, with clinical use guided by its tolerability profile and effectiveness in controlling acute gastrointestinal symptoms.
BRAND NAMES
Vogalene – the most widely recognized brand used for nausea and vomiting.
Vogalib – an orally disintegrating formulation commonly used in some regions.
MECHANISM OF ACTION
Metopimazine acts primarily as a peripheral dopamine D2 receptor antagonist. It blocks dopamine receptors in the gastrointestinal tract and in the chemoreceptor trigger zone (CTZ) of the medulla, which reduces stimulation of the vomiting center in the brain. By inhibiting dopaminergic signaling, it suppresses nausea and vomiting reflexes triggered by toxins, drugs, or gastrointestinal irritation.
PHARMACOKINETICS
Absorption:
Metopimazine is moderately absorbed after oral administration. It undergoes some first-pass metabolism, but sufficient systemic levels are achieved for its antiemetic effect. Food does not significantly alter its absorption.
Distribution:
Metopimazine is distributed mainly in peripheral tissues, with limited penetration into the central nervous system, which reduces central side effects. Plasma protein binding is moderate, allowing adequate peripheral receptor interaction, particularly in the gastrointestinal tract and chemoreceptor trigger zone.
Metabolism:
It is primarily metabolized in the liver through enzymatic biotransformation into inactive metabolites. Hepatic metabolism plays a key role in its clearance.
Elimination:
Excretion occurs mainly via the urine, with metabolites being the primary excreted form. A smaller fraction may be eliminated through bile and feces. The elimination half-life supports short-term symptomatic use.
PHARMACODYNAMICS
Metopimazine works as a dopamine D2 receptor antagonist, primarily acting on peripheral receptors in the gastrointestinal tract and centrally at the chemoreceptor trigger zone (CTZ). By blocking dopamine-mediated stimulation of the vomiting center, it reduces nausea and vomiting caused by gastrointestinal irritation, toxins, or drugs. Its limited central nervous system penetration minimizes sedative and extrapyramidal effects compared to other phenothiazines.
ADMINISTRATION
Metopimazine is administered orally in tablet or orodispersible forms. It is commonly used for short-term management of nausea and vomiting. It can be taken with or without food, depending on patient tolerance and formulation.
DOSAGE AND STRENGTH
Typical adult dosing ranges from 5–10 mg taken up to three times daily, depending on symptom severity and formulation. Pediatric dosing is lower and weight-adjusted when used. Treatment duration is usually short-term and symptom-driven.
DRUG INTERACTIONS
Metopimazine may interact with other central nervous system depressants, potentially increasing sedation. Concomitant use with other dopamine antagonists may enhance extrapyramidal effects, although this is less common due to its peripheral selectivity.
FOOD INTERACTIONS
Food does not significantly affect the absorption or effectiveness of metopimazine. It may be taken with meals if gastrointestinal irritation occurs.
CONTRAINDICATIONS
Metopimazine is contraindicated in patients with known hypersensitivity to phenothiazine derivatives. Caution is advised in patients with severe hepatic impairment or conditions where dopamine blockade may be undesirable.
SIDE EFFECTS
Common side effects include drowsiness (less frequent than other phenothiazines), dizziness, dry mouth, and mild gastrointestinal discomfort. Rarely, extrapyramidal symptoms or allergic reactions may occur.
OVER DOSAGE
Overdose of Metopimazine is uncommon and is generally associated with exaggerated pharmacological effects rather than severe life-threatening toxicity. Clinical features may include drowsiness, dizziness, confusion, dry mouth, hypotension, and gastrointestinal discomfort such as nausea or abdominal pain. In some cases, especially with high doses or susceptible individuals, extrapyramidal symptoms (such as muscle rigidity, dystonia, or tremors) may occur due to dopamine receptor blockade.
TOXICITY:
Toxicity of Metopimazine is uncommon but may include excessive sedation, hypotension, and in rare cases extrapyramidal symptoms such as dystonia or parkinsonism. Overdose is generally managed with supportive care, monitoring of vital signs, and symptomatic treatment. Severe toxicity is rare due to its predominantly peripheral action.
